Grant: Project Grant
Research Institute of the McGill University Health Centre
$1,147,500.00
Why are women at greater risk for multi-drug resistant tuberculosis?
FY 2024-25
Summary
A proven strategy to reduce tuberculosis (TB) incidence is to screen entire populations and treat identified cases; however, this is often too costly and complicated. A better strategy is to focus on populations that we know have a higher rate of TB, known as targeted TB screening.
In our recent field work in India, we found women to be almost twice as likely to have multi-drug resistant (MDR) TB than men. We hypothesize that this could be because women are often the caretakers of people with MDR-TB (and therefore could be infected that way), or because of exposure in confined spaces (such as slums) due to lower employment prospects. In addition, MDR-TB risk may be even greater for women because of higher rates of malnutrition and new HIV infections.
We will recruit TB patients of all genders in Pune, India, over 4 years: 600 will be patients with drug-resistant TB, and 600 with non-drug resistant TB. We will analyze the samples to identify the strains of TB, as well as the demographics of the patients (caretaking activities, crowding, gender, etc.), and we expect to find higher rates of transmission of MDR-TB to women, compared to men or non-MDR-TB. For a portion of these participants, we will investigate their close contacts, and test them for malnutrition, vitamin deficiencies, HIV and diabetes as well as test for TB (for up to 2 years). We expect women exposed to MDR-TB to have higher rates of malnutrition, HIV and TB than women exposed to non-MDR-TB, and men exposed to MDR-TB.
Studying MDR risk factors by gender is novel and will inform efforts in targeted active case finding in India, the country with the highest global burden of MDR-TB.
Department
Program
Project Grant
Location
Quebec, Canada
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
509435
Name
Pai Madhukar
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Clinical
Prcname2
Public, Community & Population Health 2
Projecttitle
Why are women at greater risk for multi-drug resistant tuberculosis?
Programtype2
Operating Grants
Orgnameinp2
Research Institute of the McGill University Health Centre
Cihramount2
$1,147,500
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Multi-Drug Resistant Tb; Tuberculosis; Whole-Genome Sequencing; Women
Abstract
A proven strategy to reduce tuberculosis (TB) incidence is to screen entire populations and treat identified cases; however, this is often too costly and complicated. A better strategy is to focus on populations that we know have a higher rate of TB, known as targeted TB screening.
In our recent field work in India, we found women to be almost twice as likely to have multi-drug resistant (MDR) TB than men. We hypothesize that this could be because women are often the caretakers of people with MDR-TB (and therefore could be infected that way), or because of exposure in confined spaces (such as slums) due to lower employment prospects. In addition, MDR-TB risk may be even greater for women because of higher rates of malnutrition and new HIV infections.
We will recruit TB patients of all genders in Pune, India, over 4 years: 600 will be patients with drug-resistant TB, and 600 with non-drug resistant TB. We will analyze the samples to identify the strains of TB, as well as the demographics of the patients (caretaking activities, crowding, gender, etc.), and we expect to find higher rates of transmission of MDR-TB to women, compared to men or non-MDR-TB. For a portion of these participants, we will investigate their close contacts, and test them for malnutrition, vitamin deficiencies, HIV and diabetes as well as test for TB (for up to 2 years). We expect women exposed to MDR-TB to have higher rates of malnutrition, HIV and TB than women exposed to non-MDR-TB, and men exposed to MDR-TB.
Studying MDR risk factors by gender is novel and will inform efforts in targeted active case finding in India, the country with the highest global burden of MDR-TB.
Competitiondate
202409
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Pai, Madhukar; Farhat, Maha
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $1,147,500~ $0~